LQDA NASDAQ
Liquidia Corporation
1W: -58.1%
1M: -58.9%
3M: -63.8%
YTD: -8.8%
1Y: +29.9%
3Y: +348.2%
5Y: +897.9%
$28.64
+0.65 (+2.32%)
Weekly Expected Move ±29.6%
$12
$20
$29
$37
$46
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.3M
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.5B
52W Range21.91-93.61
Volume8,389,617
Avg Volume1,700,403
Beta0.54
Dividend—
Analyst Ratings
Company Info
CEORoger A. Jeffs
Employees216
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2018-07-26
Websiteliquidia.com
419 Davis Drive
Morrisville, NC 27560
US
Morrisville, NC 27560
US
919 328 4400
About Liquidia Corporation
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Latest News
Liquidia extends losses as Wells Fargo adds to downgrades on legal setback
Liquidia (NASDAQ:LQDA) Shares Gap Down Following Analyst Downgrade
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback
Liquidia cut to Neutral at BTIG after patent win for United Therapeutics
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| SINGH RAMAN | S-Sale | 8,468 | $66.16 | 2026-09-14 |
| SINGH RAMAN | S-Sale | 9,024 | $68.62 | 2026-09-11 |
| Krepp Sarah | S-Sale | 274 | $67.76 | 2026-09-01 |
| Adair Jason | M-Exempt | 10,762 | $14.20 | 2026-08-21 |
| Adair Jason | M-Exempt | 238 | $14.20 | 2026-08-21 |